Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1β) activity is required more during early than late tumor growth
Authors:
- 12 October 2009
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 49 (2) , 157-165
Abstract
C4 is a derivative of the mouse hepatoma cell line, Hepa‐1, that harbors a mutation in the aryl hydrocarbon receptor nuclear translocator gene (Arnt, or hypoxia inducible factor 1β [HIF‐1β]) leading to loss of activity. Clone 3 cells were generated by introducing a doxycycline‐repressible Arnt expression vector into c4 cells. Clone 3 cells were injected subcutaneously into immunosuppressed mice, which were treated with doxycyline (a) throughout the growth of the subsequent tumor xenografts, or (b) from day 7 through to the end of the experiment (day 30), or not treated (c). Tumors in all groups grew exponentially between days 14 and 30, and at rates that were indistinguishable from each other. However, tumors in group a were smaller than those of the other two groups throughout the measurable growth period, while tumor volumes in groups b and c were not significantly different from each other. The degrees of vascularity and apoptosis did not correlate with the differences in degrees of growth between the different groups. Thus, Arnt is required during the early stages of growth of the tumors but less in later stages. Since Arnt does not detectably effect the growth kinetics of Hepa‐1 cells either during hypoxia or normoxia, this requirement is unlikely to reflect a direct effect of Arnt on cell proliferation, and is therefore probably a consequence of altered interaction(s) between the tumor cells and the host. These studies suggest that Arnt (and HIF‐1α/HIF‐2α) inhibitors will be particularly effective against smaller tumors, including micrometastases.Keywords
This publication has 31 references indexed in Scilit:
- Resveratrol Inhibits Dioxin-Induced Expression of Human CYP1A1 and CYP1B1 by Inhibiting Recruitment of the Aryl Hydrocarbon Receptor Complex and RNA Polymerase II to the Regulatory Regions of the Corresponding GenesToxicological Sciences, 2009
- Analysis of Ah Receptor-ARNT and Ah Receptor-ARNT2 Complexes In Vitro and in Cell CultureToxicological Sciences, 2007
- Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent MicroscopyCancer Research, 2007
- Hypoxia: A key regulator of angiogenesis in cancerCancer and Metastasis Reviews, 2007
- Hypoxia-inducible factors: central regulators of the tumor phenotypeCurrent Opinion in Genetics & Development, 2007
- A Truncated Ah Receptor Blocks the Hypoxia and Estrogen Receptor Signaling Pathways: A Viable Approach for Breast Cancer TreatmentMolecular Pharmaceutics, 2006
- The HIF pathway in cancerSeminars in Cell & Developmental Biology, 2005
- A point Mutation Responsible for Defective Function of the Aryl‐Hydrocarbon‐Receptor Nuclear Translocator in Mutant Hepa‐1c1c7 CellsEuropean Journal of Biochemistry, 1997
- Cloning and Selective Expression in Brain and Kidney of ARNT2 Homologous to the Ah Receptor Nuclear Translocator (ARNT)Biochemical and Biophysical Research Communications, 1996
- The Aryl Hydrocarbon Receptor ComplexAnnual Review of Pharmacology and Toxicology, 1995